

## **New York-specific Test Requisition Form**

## MachaonDiagnostics.com

Toll-free: (800) 566-3462

Northern California Lab (PFI: 9439) Medical Director: Brad Lewis, MD Medical Director: Gloria Coker, MD 2023 Eighth Street, Berkeley, CA 94710

New Orleans Lab (\*\*local samples can be sent directly) 8721 Oak Street, New Orleans, LA 70118

	Phone: (510) 839-5600 / Fax: (510) 8	39-6153 Phone: (504) 866-7090 / Fax: (504) 866-7091	
PATIENT HISTORY		SUBMITTING FACILITY	
Patient's Name: (Last, First, M.I.) *	Specimen Date and Time:*	Client Account #:	*= REQUIRED
loop # loop #		Facility Name and Address:*	
Sex:* DOB:* MRN:*	Ordering Provider: (Last, First)*		
	/	-	
Platelet Count(K/μL), aPTT(sec.), PT Hematocrit(%), Bleeding History(Y/N),	(sec.), INR Clotting History (Y/N)		
☐ Patient is anticoagulated Please specify:		Phone:* Fax for results:*	
☐ Patient is on antiplatelet medication ☐ dabigatran ☐ fondaparinux		STAT ASAP INSURANCE BILL IC	·D-10(c)
□ Patient is on Hemlibra therapy □ Aspirin □ Plavix □ Br New York Approved Tests (visit our websi			D-10(\$)
•	• •	☐ ADAMTS13 Antibody (STAT <24 Hours	(s)
□ aHUS Genetic Panel (20 genes); (STAT <48 Hours, M-F) □ TMA-Complete™ Genetic Panel (20 genes); (STAT <48 Hours, M-F)		□ Antithrombin III Activity	<b>o</b> ,
ADAMTS13 Activity (reflexes to ADAMTS13 Inhibitor); (STAT <24 Hours)		□ aPTT-LA (Lupus Sensitive Reagent)	
DAMTS13 Activity (reflexes to Adamts13 liffibilion), (STAT <24 Hours)  ADAMTS13 Gene Sequencing (STAT <48 Hours, M-F)		□ CXCL9 Level (STAT <24 Hours)	
·		□ dRVVT (dilute Russell Viper Venom Time)	
ACL (Anticardiolipin - IgG, IgM and IgA) Beta-2 Glycoprotein I Antibody (IgG, IgM and IgA)		☐ Fibrinogen Activity	i ililie)
□ Beta-2 Glycoprotein i Antibody (igG, igM and igA) □ Factor Activity (aPTT-based) □ test all factors		☐ Heparin Antibody ELISA (PF4) (STAT <24 Hrs)	
□ VIII (8) □IX (9) □ XI (11) □ XII (12)		☐ Lupus Anticoagulant Screen (aPTT-LA, dRVVT, ACL)	
☐ Factor Activity (PT-based) ☐ test all factors		☐ Mixing Study (aPTT) - reflex to incubated mix	
$\Box$ II (2) $\Box$ V (5) $\Box$ VII (7) $\Box$ X (10)		☐ Protein C Activity	
□ Inhibitor to Factor(s) (Bethesda Units)  □ VIII (8) □ IX (9) □ XI (11) □ XII (12)  □ II (2) □ V (5) □ VII (7) □ X (10)  □ Anti-CFH Autoantibody  □ HLH Genetic Panel 3.0 (36 genes); (STAT <48 Hours, M-F)		□ Protein S Activity	
		☐ Soluble IL-2 Receptor Alpha (STAT <24 Hours)	
		☐ Thrombin Time - TCT (confirmed w/PS)	
		□ VWF Activity (Ristocetin cofactor)	
		<ul><li>□ VWF Antigen</li><li>□ Von Willebrand Factor Profile (STAT &lt;24 Hours)</li></ul>	
		(Factor VIII Activity, VWF: Antigen, VWF: RCo an	
Tests Needing a New York Restricted Labo	ratory Permit Prior to T	esting (visit our website for permit form a	ınd updates)
☐ Modified Ham 2.0 (mHam 2.0) and sC5b-9 ☐ C3 Glomerulopathy Genetic Panel (6 genes); (STAT <48 Hours, M-F) ☐ Dysfibrinogenemia Genetic Panel (FGA, FGB, FGG)		Informed Consent for Genetic Testing - REQUIRED	) for NY Samples
		Providers are required to obtain informed consent from patients for genetic testing for all samples originating in New York. An informed consent form may be found at http://www.machaondiagnostics.com,	
		Soluble Complement 5b-9 (sC5b-9); (STAT <2-	4 Hours)
□ Hemophilia-Complete™ Genetic Panel(F8,	-9, VWF, inversions)	state healthcare providers may sign the below state	
☐ PlateletGenex™ Functional Defect Panel (3	1 genes)	that informed consent has been obtained from thei testing samples originating in NY will be destroyed	
☐ PlateletGenex™ Thrombocytopenia Panel (26 genes)		60 days after collection. No tests other than those be performed on these samples.	authorized will
Polycystic Kidney Disease (PKD) Genetic	Panel (2 genes)	be performed on these samples.	
□ Plasminogen Gene Sequencing □ CoagGenex Clotting Genetic Panel (29 genes) □ VWD-Complete™ Genetic Panel (VWF and GP1BA)		Verification of Informed Consent: I am a healthcare provider for the patient named on this requisition. I have obtained the required informed consent from the patient or the	
		Signature of Provider: D	ate:
		Note: testing may be delayed if a consent form is not received, and no	
ADDITIONAL INFORMATION		provider signature is present above.	
ADDITIONAL INFORMATION  Patients with insurance coverage other than Medicare are co	nsidered out-of-network and will	MACHAON USE ONLY	Aliguata
be billed for services not covered by their insurance provider.	Medicare patients must sign an	Specimen type received:  Specimen type received:	
ABN, either located on the reverse side of this form or downlo	Jaueu IIOIII IIIE Machaon	- position type reserved.	, quoto

Tech initials:\_\_\_

\_\_\_ Specimen received stamp: \_

N/A

Temperature indicator acceptable (circle one): Yes /

ABN, either located on the reverse side of this form or downloaded from the Machaon Diagnostics website. Patient insurance billing services are provided in accordance with the Machaon Insurance Billing Policy. Samples originating from NY-state for genetic testing are

Version-NY07FEB2025